Design Therapeutics, Inc.DSGNNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank50
3Y CAGR-43.7%
5Y CAGR-37.1%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
-43.7%/yr
Annual compound
5Y CAGR
-37.1%/yr
Recent deceleration
Percentile
P50
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
202512.78%
2024-14.64%
202311.31%
202271.72%
2021342.83%
2020129.41%
20190.00%